HUMA250117P3500
- 0.05
- 0.000.00%
Humacyte Newsroom
Humacyte Price Target Maintained With a $25.00/Share by D. Boral Capital
Humacyte Analyst Ratings
Humacyte Is Maintained at Buy by Benchmark
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $17
Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Ligand Pharma (LGND)
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $15
BTIG Sticks to Their Buy Rating for Humacyte (HUMA)
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
Humacyte Analyst Ratings
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
Promising Clinical Outcomes and Imminent FDA Approval Bolster Buy Rating for Humacyte's Bioengineered Vessel
Humacyte Is Maintained at Buy by D. Boral Capital
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $12
Humacyte Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Humacyte Analyst Ratings
Piper Sandler Maintains Humacyte(HUMA.US) With Hold Rating, Maintains Target Price $6
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $12
Humacyte Is Maintained at Buy by D. Boral Capital